This year (FY 05) profit will be above $500m with a oneoff of $200m capital gain. This is a far cry from $70mil, 2 years ago.
With FDA approval early next year for HPV then a oneoff bonus payment from Merck comes in.
Are we looking at a cheap (PE) company as this one-off have not been factored in?
After all once HPV vaccine hits the market an extra 150-200m annual addition on profit is on the card as well...
buy buy buy buy buy - , page-2
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$302.04 |
Change
4.380(1.47%) |
Mkt cap ! $145.9B | |||
| Open | High | Low | Value | Volume |
| $300.00 | $302.49 | $299.34 | $178.5M | 592.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 285 | $302.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $302.10 | 67 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |